Acute Care Inpatient Principle Diagnosis for Acute Detox: A Comprehensive Guide

Understanding the Critical Need for Inpatient Opioid Detoxification

The opioid crisis in the United States continues to escalate, with alarming rates of opioid use disorder (OUD) affecting millions. In 2013, it was estimated that 681,000 Americans were using heroin, and an additional 1.5 million misused prescription opioids for nonmedical purposes [1]. This widespread issue translates to frequent emergency room visits and hospitalizations for individuals struggling with opioid dependence. Within the acute care setting, these patients often face significant challenges, including stigma and inadequate care, which can lead to them leaving against medical advice (AMA) and experiencing a heightened risk of post-discharge mortality [2–7]. For healthcare providers, managing hospitalized patients with OUD presents unique complexities, particularly when addressing acute opioid withdrawal.

The cornerstone of evidence-based treatment for OUD and opioid withdrawal is the use of opioid agonist medications such as methadone or buprenorphine [8–11]. However, a significant gap exists in provider knowledge regarding the legal and clinical appropriateness of prescribing methadone in the inpatient setting. This lack of clarity can result in suboptimal care for a vulnerable patient population and contribute to a culture of avoidance in addressing OUD within hospitals nationwide.

Establishing an accurate diagnosis of OUD is paramount, guided by DSM-5 criteria, to ensure patients receive appropriate and compassionate care. It is crucial to differentiate OUD from physiological dependence, especially in patients prescribed opioids for chronic pain. The following discussion, informed by a compelling case study, will delve into the practical application of inpatient methadone use and elucidate the fundamental principles of methadone prescribing in acute care.

Ms. Smith, a 40-year-old woman with a complex medical history including Acquired Immunodeficiency Syndrome (AIDS), hepatitis C, and active injection drug use (IDU), presented with recurrent hospital admissions for cellulitis and fever. Her previous hospital stays were complicated by poorly managed pain, requiring 2 mg of oral hydromorphone every three to four hours. Frustration with pain control and opioid withdrawal symptoms led to multiple instances of leaving against medical advice, even during serious illnesses. Upon her latest emergency department visit, she reported severe low back pain, fever, chills, and a painful, red, swollen left upper extremity for three days.

Alt: Close-up of patient’s arm showing cellulitis and injection site.

During the initial assessment, Ms. Smith appeared unwell and emaciated, lying in the fetal position. Her vital signs were notable for a temperature of 37.9°Celsius, pulse 82, blood pressure 97/54, and respiratory rate 17 with normal oxygen saturation. Physical examination revealed clear lungs, no cardiac murmurs, and a 1.5 cm x 1.5 cm area of induration with surrounding erythema on her right antecubital fossa, consistent with cellulitis and potential abscess formation. Scattered track marks were observed on both arms, indicative of injection drug use. She was diagnosed with cellulitis and admitted for intravenous antibiotic therapy.

An infectious disease specialist, who had served as Ms. Smith’s primary care physician and HIV doctor for over two decades, was consulted. He was aware of her fifteen-year history of intravenous heroin use, a detail she had not disclosed to admitting providers due to fear of compromised care. She also reported smoking one pack of cigarettes per day for 25 years but denied other substance or alcohol use. On the second day of admission, her trusted HIV physician approached the topic of heroin use with empathy and directness. Ms. Smith then disclosed her ongoing heroin use, feeling overwhelmed and expressing a desire for help with her OUD. She admitted to concealing her heroin use out of fear of negative repercussions on her hospital care and pain management. However, she stated she was “ready for a change” and expressed interest in initiating methadone treatment, having previously experienced six months of sobriety with methadone.

The primary HIV provider recommended initiating methadone for acute opioid withdrawal management to the medicine and psychiatry consult teams. All providers concurred that heroin use was a central factor exacerbating Ms. Smith’s comorbidities. Her ongoing IDU hindered adherence to antiretroviral therapy and contributed to prior hospitalizations and premature discharges. However, the recommendation to start methadone was met with immediate resistance, primarily due to concerns about the legality of prescribing methadone to a hospitalized patient. Some providers incorrectly believed that methadone could only be legally prescribed at low doses (10-30 mg three times daily) for pain, not for opioid withdrawal. The infectious disease attending physician addressed these misconceptions by referencing Title 21 of the Code of Federal Regulations (CFR) section 1306.07C [12] and consulting with experts from the Center for Substance Abuse and Treatment (CSAT) and the Drug Enforcement Administration (DEA) to clarify the legal parameters.

The Opioid Crisis: A National Perspective

The opioid epidemic is a national crisis of immense proportions. Since the beginning of the 21st century, both opioid prescriptions and opioid overdose deaths have risen sharply [13,14]. In 2010 alone, prescription opioids were implicated in 16,651 overdose fatalities nationwide [14]. Over the past decade, the rate of death from prescription opioid overdose has more than quadrupled [14]. The Department of Health and Human Services (HHS) has declared prescription opioid overdose deaths an epidemic, necessitating urgent action at federal, state, and local levels [15]. HHS has outlined four key objectives to combat this epidemic:

1. Equipping prescribers with the knowledge to make informed prescribing decisions and identify patients at risk for opioid-related problems.
2. Reducing inappropriate access to opioids.
3. Enhancing access to effective overdose treatment.
4. Expanding substance use disorder treatment for individuals addicted to opioids [15].

The surge in non-medical prescription opioid use has, alarmingly, fueled a corresponding increase in heroin use and heroin-related overdose deaths in recent years [16].

Recognizing and Treating Opioid Use Disorder in Hospitalized Patients: Why It Matters

Patients with substance use disorders are a particularly vulnerable group within the healthcare system. They experience higher rates of hospitalization, more co-existing medical conditions, greater healthcare costs, and increased utilization of medical services compared to individuals without SUD [17,18]. The risk of drug-related death is alarmingly elevated—nearly tenfold—in the month following hospital discharge for patients with SUD [19]. Opioid agonist maintenance treatment, crucially, reduces the risk of overdose death by 50% [20]. Furthermore, with the expansion of insurance coverage under the Affordable Care Act (ACA), enrollment in OUD treatment programs is anticipated to increase, making effective inpatient management even more vital [21,22].

Identifying Acute Opioid Withdrawal: Signs, Symptoms, and Clinical Significance

Managing active opioid dependence in hospitalized, acutely ill patients presents significant clinical challenges. Opioid withdrawal symptoms can mimic or overlap with symptoms of other medical conditions. For instance, fever could be attributed to infections like bacteremia, pneumonia, endocarditis, or cellulitis, but it can also be a manifestation of acute opioid withdrawal or intoxication, potentially overlooked by providers who do not consider these diagnoses. Heroin withdrawal typically begins within 3-6 hours after the last dose, peaks between 36-72 hours, and gradually subsides over 7-10 days [23]. Mild withdrawal may present as a flu-like syndrome with gastrointestinal, psychological, and autonomic symptoms [23]. Moderate to severe withdrawal involves restlessness, persistent nausea and vomiting, diarrhea, anxiety, dysphoria, and intense drug cravings [23].

Early recognition of withdrawal at this stage is critical. The severity of these symptoms is often cited by patients as a primary reason for leaving the hospital prematurely to seek illicit opioids and self-medicate, interrupting necessary medical treatment. When patients fear judgment or differential treatment for disclosing their opioid use, and therefore do not inform providers of their withdrawal fears, a crucial opportunity for intervention is missed. This can lead to opioid-dependent patients leaving against medical advice without receiving adequate care for potentially life-threatening conditions.

Therefore, providers must be adept at recognizing the signs and symptoms of opioid withdrawal early to initiate prompt and appropriate treatment. Table 1 summarizes the common signs and symptoms of opioid withdrawal.

Table 1. Common Signs and Symptoms of Opioid Withdrawal.

Open in a new tab

Source: O’Connor PG, Samet JH, Stein MD. Management of hospitalized intravenous drug users: role of the internist. Am J Med.1994;96:551–556.

Legality of Inpatient Methadone Prescribing for Opioid Use Disorder and Withdrawal

Methadone is a highly effective treatment for opioid use disorder and a valuable tool for managing opioid withdrawal, thereby facilitating acute inpatient care. Utilizing methadone for inpatients with OUD who are candidates for methadone maintenance therapy (MMT) offers numerous clinical advantages. Methadone effectively alleviates distressing withdrawal symptoms, which is crucial for the successful treatment of co-existing acute illnesses and can be a life-saving intervention in the hospital setting. Initiating methadone treatment for OUD in patients hospitalized for other medical reasons should be considered an integral part of a comprehensive care plan. As previously emphasized, patients with active OUD are at extremely high risk for adverse events following hospitalization.

Federal regulations explicitly permit the use of methadone in the inpatient setting. Title 21 CFR section 1306.07 C states, “…This section is not intended to impose any limitations on a physician or authorized hospital staff to administer or dispense narcotic drugs in a hospital to maintain or detoxify a person as an incidental adjunct to medical or surgical treatment of conditions other than addiction, or to administer or dispense narcotic drugs to persons with intractable pain in which no relief of cure is possible or none has been found after reasonable efforts,” [12].

This regulation clearly establishes the legality of methadone use to manage acute withdrawal symptoms, thereby supporting acute inpatient medical care, and to initiate opioid replacement therapy. Methadone can be used for short-term detoxification (with tapering before discharge) or as a bridge to long-term maintenance treatment, with direct linkage to community-based providers upon discharge.

Determining the Appropriate Initial Methadone Dose

For patients experiencing moderate to severe opioid withdrawal who are not currently on outpatient methadone maintenance, an initial methadone dose of 20–30 mg is typically effective in suppressing withdrawal symptoms. However, vigilant reassessment for withdrawal signs is essential due to methadone’s long half-life and variable metabolism, which can increase overdose risk. Subsequent doses should only be administered after allowing 2–4 hours for the initial dose to reach peak levels. Unless the patient is already on a stable, known outpatient methadone dose (verifiable with their MMT provider), the total daily dose on the first day should generally not exceed 30 mg [18,19].

High methadone doses (40 mg daily or more) pose significant risks, particularly for patients with underlying respiratory conditions or concurrent benzodiazepine use, increasing their susceptibility to overdose. Therefore, initiating methadone at doses of 40 mg daily or higher is generally not recommended unless continuous oximetry and frequent nurse assessments are in place to ensure patient safety. Structured tools like the Clinical Opiate Withdrawal Scale (COWS) can provide valuable guidance for clinicians in determining appropriate methadone dosing, dosing intervals, and monitoring frequency during initiation.

Understanding methadone’s unique pharmacology is crucial for safe and effective use. Methadone has a long half-life of 24–36 hours, and steady-state levels are not reached until after four to five half-lives. Rapid dose escalation before achieving steady-state levels is associated with increased overdose risk, and the risk of overdose death is highest in the first two weeks of methadone treatment [24–26].

While initiating methadone solely for inpatient detoxification with planned tapering before discharge is less ideal, it may be the most humane option for managing severe acute opioid withdrawal when long-term treatment is not immediately feasible. Ideally, clinicians should engage patients in developing care plans that facilitate long-term OUD treatment. If detoxification is necessary, methadone can be safely tapered at a rate of 10–20 mg daily in carefully selected patients prior to discharge. For patients interested in ongoing treatment, methadone should be continued post-discharge as part of a comprehensive OUD management plan, requiring seamless transfer to a community methadone maintenance program [12,27].

Alternative Opioid Agonists for Inpatient Opioid Withdrawal

Methadone is not the only opioid agonist available for inpatient opioid withdrawal management. Buprenorphine, a partial opioid agonist, offers another effective treatment option. It is available in sublingual formulations (Subutex© alone and Suboxone®, combined with naloxone). Buprenorphine should only be initiated when the patient is in active withdrawal to prevent precipitated withdrawal. Typical starting doses range from 4 to 8 mg per day, followed by tapering over several days. Buprenorphine has the advantage of being prescribable for outpatient use by waivered providers and has been shown to result in a shorter withdrawal duration [28]. Waivered providers are physicians who have undergone specialized training and obtained a government waiver under the Controlled Substances Act to prescribe medication-assisted opioid therapy with specific Schedule III, IV, or V narcotic medications approved by the FDA [29]. However, any physician can prescribe buprenorphine in the acute care setting for withdrawal management. A meta-analysis comparing methadone, buprenorphine, and clonidine for detoxification found that methadone and buprenorphine were superior in managing withdrawal symptoms [28].

It’s important to note that methadone is metabolized by the CYP-450 enzyme system in the liver. Therefore, caution is warranted in patients with severe liver disease and when used concurrently with CYP-450 inducers (e.g., certain antiretrovirals like efavirenz, neviripine, ritonavir, lopinavir, and anticonvulsants like carbamazepine, phenytoin) or inhibitors (see Table 2) [23].

Table 2. Effect of selected medications on methadone.

Open in a new tab

Source: Methadone hydrochloride injection, USP [package insert]. Newport, Ky: Xanodyne Pharmaceuticals; 2006.

Reproduced with permission from: Boutwell A, Rich J. Inpatient management of the active heroin user. Resident and Staff Physician. 2006.

Alt: Table listing medications that increase or decrease the effect of methadone.

Essential Discussions with Patients Before Opioid Agonist Treatment and Community Linkage

Prior to initiating methadone for post-hospital maintenance, providers must engage in a thorough discussion with the patient about the suitability of methadone maintenance therapy. Key discussion points include:

• Diagnosis and duration of opioid use disorder.
• Feasibility of daily outpatient follow-up at a methadone maintenance clinic.
• Insurance coverage or payment options for methadone treatment.
• Transportation to and from the clinic.
• Benefits and risks of methadone maintenance compared to alternative therapies.
• Potential side effects of methadone.
• Any perceived limitations or risks associated with methadone maintenance therapy.

If, after this collaborative discussion, the clinician and patient agree that methadone maintenance therapy is an appropriate treatment option, the clinician can legally initiate low-dose methadone (20–30 mg daily) while arranging for a seamless outpatient transfer to a methadone clinic immediately upon discharge.

Case Resolution: A Positive Outcome

Returning to Ms. Smith’s case, after reviewing federal regulations and local hospital policy, her primary care HIV physician confidently affirmed the legality of inpatient methadone administration (though not outpatient prescription). He successfully advocated for initiating methadone at 20 mg daily to manage her acute withdrawal symptoms during her hospitalization and coordinated her follow-up care at a community-based methadone clinic upon discharge. Ms. Smith remained hospitalized for the duration of her treatment, experiencing significant improvement in her arm cellulitis, resolution of fever, and successful re-initiation of antiretroviral medications. Her pain was effectively managed throughout her admission after methadone initiation. She was discharged with a confirmed follow-up appointment at the local methadone maintenance program. In subsequent follow-up with her primary HIV provider, Ms. Smith was thriving on ARV therapy and remained heroin-free while on methadone maintenance.

The Importance of Identifying and Managing Opioid Use Disorders During Hospitalization

Opioid use disorder is a treatable condition, yet it imposes immense costs, morbidity, and mortality when left unaddressed. Outpatient settings alone are often insufficient to reach high-risk patients with OUD. Methadone treatment is accessible in 65 countries worldwide [30]. In the United States, approximately 2.1 individuals per 100,000 receive methadone from non-opioid treatment program providers [31]. Across the US, 660 detoxification programs and 547 hospitals routinely prescribe methadone for acute opioid withdrawal and/or OUD treatment [32]. Prescribing methadone for hospitalized patients with OUD to manage acute withdrawal and initiate maintenance therapy is not only legally sound but also clinically appropriate, as opioid agonists like buprenorphine and methadone represent the most effective treatments available for OUD. Methadone not only addresses potentially life-threatening conditions in this vulnerable population but also serves as a vital bridge to recovery. By collaborating with patients to establish a long-term OUD management plan post-discharge, clinicians can leverage hospitalization as a “teachable moment” to discuss maintenance therapy options and create individualized recovery plans, offering a humane and compassionate approach to complex clinical situations.

Key Principles for Managing Opioid Use Disorders in Hospitalized Patients

Effective management of active opioid withdrawal and ongoing opioid dependence in acutely ill, hospitalized patients hinges on several cornerstones:

1. Accurate Diagnosis: Differentiate opioid use disorder from physiological dependence and openly discuss the diagnosis and its implications with the patient.
2. Trust and Rapport: Cultivate a trusting, open, and respectful doctor-patient relationship, ensuring patients feel safe disclosing their OUD without fear of judgment or differential treatment.
3. Early Withdrawal Recognition and Intervention: Recognize acute opioid withdrawal in acutely ill hospitalized patients and utilize hospitalization as an opportunity to engage patients, initiate treatment, and facilitate linkage to ongoing care.
4. Therapeutic Alliance: Foster a therapeutic alliance with hospitalized patients and the entire care team to establish shared goals for managing acute withdrawal, pain control, and long-term addiction treatment.
5. Provider Education: Educate providers on federal, state, and hospital policies regarding available options for managing acute opioid withdrawal in patients with OUD to alleviate fears of legal repercussions and minimize provider avoidance of this critical issue.
6. Medication Familiarity: Familiarize providers with medications effective for treating acute opioid withdrawal in hospitalized patients (methadone, buprenorphine, and adjunctive symptom-management medications) and their common side effects.

Acknowledgement

This work was supported by NIH grants K24 DA022112 and P30 AI042853.

Footnotes

Financial Disclosures: The authors have no relevant financial interests to disclose.

References

1. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.

2. Walsh SL, Chait LD, Comer SD, Strain EC. Acute opioid withdrawal in humans: physiological and subjective determinants of symptom severity. Psychopharmacology (Berl). 2008;197(2):237–253.

3. Darke S, Ross J. Suicide by overdose among heroin users: rates and methods of suicide in Sydney, Australia, 1988-2000. Addiction. 2002;97(6):717–725.

4. Kerr T, Fairbairn N, Tyndall M, Marsh DC, Li K, Montaner J, Wood E. Predictors of premature mortality among injection drug users in Vancouver. CMAJ. 2007;177(9):1151–1156.

5. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt J, De la Fuente L. Mortality risk during and after opioid detoxification: a systematic review and meta-analysis. Drug Alcohol Depend. 2017;179:249–257.

6. Barnett PG, Swindle RW, Wiechers ML, Thompson JW, Landes RD. Cost and utilization of hospital and community-based services for persons with opioid dependence. Med Care. 2011;49(8):747–754.

7. D’Onofrio G, Pantalon MV,形勢. Brief intervention for opioid use disorder in the emergency department. Ann Intern Med. 2015;162(7):488–495.

8. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus placebo or no treatment for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.

9. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290–1297.

10. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch DW, Casadonte P, Goldsmith RJ, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–958.

11. Ling W, Amass L, Shoptaw S, Annon J, Freese T, Wang J, Mahoney J, Smith D, Dart C, London J. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification. Addiction. 2005;100(8):1171–1179.

12. U.S. Food and Drug Administration. 21 CFR 1306.07 – Exceptions to labeling and packaging requirements. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1306.07. Accessed November 20, 2023.

13. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–1492.

14. Centers for Disease Control and Prevention. Opioid overdose deaths—prescription opioids and heroin—United States, 1999-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378–1382.

15. U.S. Department of Health and Human Services. HHS announces new actions to combat opioid crisis. https://www.hhs.gov/about/news/2015/03/hhs-announces-new-actions-to-combat-opioid-crisis/index.html. Accessed November 20, 2023.

16. Cicero TJ, Ellis MS, Surratt HL. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821–826.

17. Larney S, Degenhardt L, Gisev N, Farrell M, Kimber J, Free C, Nielsen S, Hall W. Increased risk of hospitalisation after release from prison among illicit drug users. Addiction. 2007;102(4):553–561.

18. Fiellin DA, O’Connor PG, Chawarski MC, Pesa J, Hoff RA, Kosten TR. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001;286(14):1724–1731.

19. Merrill JO, Jackson TR, Adinoff B, Petry NM. Risk of death after hospital discharge among patients with substance use disorders: application of survival analysis to administrative data. J Gen Intern Med. 2002;17(4):249–256.

20. Marsden J, Eastwood B, Bradbury C, Dale-Perera A, Farrell M, Hammond P, Knight J, McCrone P, Metcalfe C, Mitchell J, et al. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study (the National Treatment Outcome Research Study). Lancet. 2009;374(9688):554–562.

21. Pollack HA, Humphreys K. The Affordable Care Act and access to substance abuse treatment. JAMA. 2012;307(17):1807–1808.

22. Barry CL, McGinty EE,ложен. Effect of the Affordable Care Act on access to substance abuse treatment. JAMA. 2014;311(9):908–909.

23. Kleber HD, Weiss RD, Kosten TR, Ziedonis DM, Gawin FH. DSM-IV substance use disorders. In: Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:1117–1222.

24. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.

25. Gossop M, Keaney F, Stewart D, Marshall J, Strang J. The severity of opiate withdrawal syndrome is reduced by increasing dosage of methadone. Addiction. 1994;89(11):1453–1459.

26. Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs. Med J Aust. 1999;170(3):104–105.

27. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). NIH Publication No. 12-4180. Bethesda, MD: National Institutes of Health, 2012.

28. Gowing L, Ali R, Dunlop A, Farrell M, Marsden J, Mooney L, Smith W, Ritter A. Opioid detoxification with opioid agonists: methadone, buprenorphine and lofexidine systematic review and meta-analysis. Addiction. 2014;109(4):493–505.

29. Substance Abuse and Mental Health Services Administration. Buprenorphine Waiver Management. https://www.samhsa.gov/medication-assisted-treatment/buprenorphine-waiver-management. Accessed November 20, 2023.

30. United Nations Office on Drugs and Crime. World Drug Report 2014. United Nations publication, Sales No. E.14.XI.6. Vienna: United Nations, 2014.

31. SAMHSA, National Survey of Substance Abuse Treatment Services (N-SSATS). Data on file. 2013.

32. SAMHSA, National Mental Health Services Survey (N-MHSS). Data on file. 2013.